This report analyzes the disruptive themes that have driven M&A activity in 2022 in the Pharma Sector
The pharma sector saw 784 M&A deals valued at $126 billion in 2022, a drop of 44% from 2021 in terms of deal value. The M&A activity dropped in most regions in 2022 compared to the previous year. North America continued to lead, with 385 deals worth $75 billion in 2022.
The pharma sector saw 784 M&A deals valued at $126 billion in 2022, a drop of 44% from 2021 in terms of deal value. The M&A activity dropped in most regions in 2022 compared to the previous year. North America continued to lead, with 385 deals worth $75 billion in 2022.
Scope
- This report provides an overview of merger and acquisition activity globally in 2022 in Pharma Sector
- It identifies the themes driving most notable to deals announced in 2022 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A)
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future
Table of Contents
- Executive Summary
- Review of the pharma M&A deals in 2022
- Themes driving the pharma M&A deals in 2022
- Appendix 1: Deal selection criteria
- Appendix 2: Our thematic research methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen
- Pfizer
- Takeda Pharma
- Bristol Myers Squibb
- Biocon Biologics
- Thermo Fisher Scientific
- Samsung Biologics
- GSK
- UCB
- Sumitovant Biopharma
- Incyte
- Merck & Co
- Eli Lilly
- Social Capital Suvretta
- Global Cord Blood
- Merck Group
- Formycon
- Collegium Pharma
- Isleworth Healthcare
- LG Chem
- Horizon Therapeutics
- Biohaven Pharma
- Nimbus Therapeutics
- Turning Point Therapeutics
- Viatris
- The Binding Site Group
- Biogen
- Sierra Oncology
- Zogenix
- Myovant Sciences
- Villaris Therapeutics
- Imago BioSciences
- Akouos
- ProKidney
- Cellenkos
- Exelead
- Athos
- BioDelivery Sciences
- Cytovia
- AVEO Oncology
